Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia

Affiliations

¹ Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
² Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 710, Taiwan. Electronic address: dtmed141@gmail.com.

Comment

Hung-Jen Tang et al. Lancet Infect Dis. 2020 Jan.

. 2020 Jan;20(1):20.

doi: 10.1016/S1473-3099(19)30693-0.

¹ Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
² Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 710, Taiwan. Electronic address: dtmed141@gmail.com.

No abstract available

Comment on

Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG. Kollef MH, et al. Lancet Infect Dis. 2019 Dec;19(12):1299-1311. doi: 10.1016/S1473-3099(19)30403-7. Epub 2019 Sep 25. Lancet Infect Dis. 2019. PMID: 31563344 Clinical Trial.